External broker reports(aggregated public sources), Daishin Securities

Daishin Securities

External broker reports(aggregated public sources)

Founded in 1962, Daishin Securities is a leading financial services provider in Korea. Daishin securities does its best to provide high quality financial service and to satisfy the various needs of investors. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>1Q24 reports consolidated revenue of W946.9bn(+31% yoy), OP of W221.3bn (+15% yoy)</li><li>Beat consensus owing to an increase in plant 4 operation rate and new bs product sales</li><li>Successful contract wins for plant 5, preparation for bs product launch on track</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

1Q24 reports consolidated revenue of W946.9bn(+31% yoy), OP of W221.3bn (+15% yoy)Beat consensus owing to an increase in plant 4 operation rate and new bs product salesSuccessful contract wins for plant 5, preparation for bs product launch on trackContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Samsung Biologics - Decent Earnings, Successful Contract Wins in Q1

South Korea

Samsung Biologics Co.,Ltd. manufactures bio-healthcare products. The Company develops, refines, and distributes biopharmaceutical products.

Samsung Biologics (207940 KS)

Samsung Biologics - Decent Earnings, Successful Contract Wins in Q1

1Q24 reports consolidated revenue of W946.9bn(+31% yoy), OP of W221.3bn (+15% yoy). Beat consensus owing to an increase in plant 4 operation rate...

Daishin Securities